Amgen's Humira biosim is one step closer to FDA approval. But how close is it to market?

Amgen ($AMGN) is one step closer to winning an FDA approval for its biosimilar of AbbVie's ($ABBV) Humira. But it's still no closer to bringing it to market. On Monday, the California drugmaker said the agency had accepted its application for so-called ABP 501--but earlier this month, the U.S. Patent and Trademark Office shut down its challenge to Humira's patents. That means it'll be up to Amgen to upturn the IP shields in court, something it says it plans to do. However, that process could delay the biotech's plans to market its copy by 2017. Story from FierceBiotech | More

Read more on